NEW YORK, January 13, 2014 /PRNewswire/ --
Today, Analysts' Corner announced new research reports highlighting McKesson Corporation (NYSE :MCK ), Omnicare, Inc. (NYSE :OCR ), HealthSouth Corporation (NYSE :HLS ), Kindred Healthcare, Inc. (NYSE :KND ), and Geron Corporation (NASDAQ :GERN ). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
McKesson Corporation Research Report
On January 6, 2014, McKesson Corporation's subsidiary McKesson Specialty Health (McKesson Specialty) and The US Oncology Network jointly announced the appointment of Jeffrey Kao as Chief Information Officer and Senior Vice President of Information & Technology Services. According to the Company, in his new role, Kao will be responsible for overseeing all support technologies for practices in The US Oncology Network, overseeing the internal technology infrastructure, and delivering innovative, advanced technology solutions to support the physicians and customers of McKesson Specialty. "Jeff has a proven track record in planning, building and deploying industry-leading technologies - both internally and externally," said Marc Owen, President of McKesson Specialty. "We believe that Jeff is the right person to guide our organization to the next stage of healthcare technology innovation, and help our customers and The US Oncology Network physicians achieve their clinical and operational goals in a safe, efficient manner." The Full Research Report on McKesson Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Omnicare, Inc. Research Report
On January 7, 2014, Omnicare, Inc. (Omnicare) announced its participation at the 32nds Annual J.P. Morgan Healthcare Conference in San Francisco, California. The Company informed that it is scheduled to make a presentation at the aforesaid conference on January 14, 2014 at 3:00 p.m. PT / 6:00 p.m. ET. According to the Company, the presentation will be broadcast live over the Internet and can be accessed from Omnicare's Investor Relations website. The Full Research Report on Omnicare, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
HealthSouth Corporation Research Report
On January 8, 2014, HealthSouth Corporation (HealthSouth) announced that it will report its Q4 2013 results on February 19, 2014, after the market closes. The Company informed that it will host an investor conference call on the following day, February 20, 2014, at 9:00 a.m. ET, to discuss the results. HealthSouth stated that the conference call will also be webcast live via its website, wherein a replay of the same will be available, beginning approximately two hours after the completion of the call, from February 20, 2014 until March 6, 2014. The Full Research Report on HealthSouth Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Kindred Healthcare, Inc. Research Report
On January 8, 2014, Kindred Healthcare, Inc. (Kindred Healthcare) announced that it will be presenting at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco on January 15, 2014. The Company informed that its CEO Paul J. Diaz is scheduled to make a presentation on the aforesaid date at 9:30 a.m. PT / 12:30 p.m. ET. Kindred Healthcare stated that an audio webcast of the presentation and any written materials accompanying the presentation can be accessed at the Company's website. The Full Research Report on Kindred Healthcare, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
Geron Corporation Research Report
On January 8, 2014, Geron Corporation (Geron) announced that it will be participating at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco. According to the Company, John Scarlett, M.D., President and CEO of Geron, will present an overview of the Company, including plans for further development of its telomerase inhibitor, imetelstat, in myelofibrosis, on January 15, 2014 at 1:30 p.m. PT. The Full Research Report on Geron Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at:
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Nidhi Vatsal, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts' Corner